The utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC

Drew Moghanaki shared a post on X:

“A new publication from Max Diehn‘s group re-demonstrates the utility of ctDNA clearance for personalizing consolidation immunotherapy after CRT for stage III NSCLC.

Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).